Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Akebia Therapeutics's enterprise value was $49.91M on Nov 11, 2026, against $298.56M a year earlier. Over the last 5 years it ranged from -$32.14M to $895.61M, with a median of $232.35M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $49.91M | -83.7% |
| 2025 | Dec 31, 2025 | $306.52M | -24.2% |
| 2024 | Dec 31, 2024 | $404.59M | +77.5% |
| 2023 | Dec 29, 2023 | $227.95M | +840.4% |
| 2022 | Dec 30, 2022 | $24.24M | -91.5% |
| 2021 | Dec 31, 2021 | $284.51M | +36.3% |
| 2020 | Dec 31, 2020 | $208.67M | -65.5% |
| 2019 | Dec 31, 2019 | $605.61M | – |
| 2018 | Dec 31, 2018 | -$74.68M | -120.0% |
| 2017 | Dec 29, 2017 | $372.54M | +57.3% |
| 2016 | Dec 30, 2016 | $236.89M | +1.7% |
| 2015 | Dec 31, 2015 | $232.94M | +97.6% |
| 2014 | Dec 31, 2014 | $117.91M | – |
See a number that looks wrong?